Skip to main content
SpringerLink
Log in

Aspirin and Antiplatelet Agent Resistance

Implications for Prevention of Secondary Stroke

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Oral antiplatelet drugs, including aspirin, clopidogrel and extendedrelease dipyridamole, are widely prescribed for the secondary prevention of vascular events, including stroke. Despite the benefits of antiplatelet therapy, 10–20% of patients experience a recurrent vascular event while taking antiplatelet medication. This article discusses the concept of antiplatelet resistance in general, focusing on aspirin resistance in particular, as a poorly defined cause of recurrent vascular events. Factors such as the lack of a standardized method to diagnose aspirin resistance and a poor clinical correlation with laboratory assays make the treatment of aspirin nonresponders difficult. In addition, there are confounding conditions such as diabetes mellitus that can affect aspirin resistance and determine a different course of treatment for these patients. Other antiplatelet options may also have resistant subpopulations; thus, alternative strategies for the secondary stroke patient must be explored.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126(3 Suppl. ): 234S–64S

    Article  PubMed  CAS  Google Scholar 

  2. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008 May; 39: 1–6

    Article  Google Scholar 

  3. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 Jan; 324: 71–86

    Article  Google Scholar 

  4. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004 Oct; 292: 1867–74

    Article  PubMed  CAS  Google Scholar 

  5. Lordkipanidzé M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007 Jul; 28: 1702–8

    Article  PubMed  Google Scholar 

  6. Altman R, Luciardi HL, Muntaner J, et al. The antithrombotic profile of aspirin: aspirin resistance or simply failure? Thromb J 2004 Jan; 2: 1 [online]. Available from URL: http://www.thrombosisjournal.com/content/2/1/1 [Accessed 2010 Sep 13]

    Article  PubMed  Google Scholar 

  7. U.S. Food and Drug Administration. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use: final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Fed Regist 1998; 63: 56802–19

    Google Scholar 

  8. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126(3 Suppl. ): 483S–512S

    Article  PubMed  CAS  Google Scholar 

  9. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991 Oct; 325: 1261–6

    Article  Google Scholar 

  10. Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007 May; 297: 2018–24

    Article  PubMed  CAS  Google Scholar 

  11. Diener HC, Bogousslavsky J, Brass LM, et al., MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004 Jul; 364: 331–7

    Article  PubMed  CAS  Google Scholar 

  12. Yusuf S, Zhao F, Mehta SR, et al., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 Aug; 345: 494–502

    Article  PubMed  CAS  Google Scholar 

  13. Bhatt DL, Fox KA, Hacke W, et al., CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 Apr; 354: 1706–17

    Article  PubMed  CAS  Google Scholar 

  14. Patrignani P, Renda G, Tacconelli S, et al. Response to pharmacodynamic interaction between aspirin and ibuprofen: a plausible mechanism of aspirin resistance. Clin Pharmacol Ther 2008 Jun; 83: 812–3

    Article  CAS  Google Scholar 

  15. Adebayo GI, Williams J, Healy S. Aspirin esterase activity: evidence for skewed distribution in healthy volunteers. Eur J Intern Med 2007 Jul; 18: 299–303

    Article  PubMed  CAS  Google Scholar 

  16. Gresner P, Dolník M, Waczulíková I, et al. Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: a role of plasma esterases. Biochim Biophys Acta 2006 Feb; 1760: 207–15

    Article  PubMed  CAS  Google Scholar 

  17. Cuisset T, Frere C, Quilici J, et al. Aspirin noncompliance is the major cause of “aspirin resistance” in patients undergoing coronary stenting. Am Heart J 2009 May; 157(5): 889–93

    Article  PubMed  CAS  Google Scholar 

  18. Hamann GF, Weimar C, Glahn J, et al., German Stroke Data Bank. Adherence to secondary stroke prevention strategies: results from the German Stroke Data Bank. Cerebrovasc Dis 2003; 15(4): 282–8

    Article  PubMed  Google Scholar 

  19. U.S. Food and Drug Administration. Concomitant use of ibuprofen and aspirin: potential for attenuation of the antiplatelet effect of aspirin [online]. Available from URL: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM16128pdf [Accessed 2009 Dec 14]

  20. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001 Dec 20; 345(25): 1809–17

    Article  PubMed  CAS  Google Scholar 

  21. Cox D, Maree AO, Dooley M, et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006 Aug; 37(8): 2153–8

    Article  PubMed  CAS  Google Scholar 

  22. Karha J, Rajagopal V, Kottke-Marchant K, et al. Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J 2006 May; 151: 976.e7-e11

    Article  PubMed  CAS  Google Scholar 

  23. Guthikonda S, Lev EI, Patel R, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007 Mar; 5: 490–6

    Article  PubMed  CAS  Google Scholar 

  24. Hankey GJ, Eikelboom JW. Aspirin resistance. BMJ 2004 Feb; 328: 477–9

    Article  PubMed  Google Scholar 

  25. Cheng G, Shan J, Xu G, et al. Relationship between endothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart disease. J Clin Pharm Ther 2007 Jun; 32: 287–92

    Article  PubMed  CAS  Google Scholar 

  26. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008 Aug; 66: 222–32

    Article  PubMed  Google Scholar 

  27. Weber AA, Przytulski B, Schanz A, et al. Towards a definition of aspirin resistance: a typological approach. Platelets 2002 Feb; 13: 37–40

    Article  PubMed  CAS  Google Scholar 

  28. Hohlfeld T, Weber AA, Junghans U, et al. Variable platelet response to aspirin in patients with ischemic stroke. Cerebrovasc Dis 2007; 24: 43–50

    Article  PubMed  CAS  Google Scholar 

  29. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002 Apr; 105: 1650–5

    Article  PubMed  CAS  Google Scholar 

  30. Meen O, Brosstad F, Khiabani H, et al. No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest 2008; 68: 185–91

    Article  PubMed  CAS  Google Scholar 

  31. Hovens MM, Snoep JD, Eikenboom JC, et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007 Feb; 153: 175–81

    Article  PubMed  CAS  Google Scholar 

  32. Dorsch MP, Lee JS, Lynch DR, et al. Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother 2007 May; 41: 737–41

    Article  PubMed  CAS  Google Scholar 

  33. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003 Mar; 41: 961–5

    Article  PubMed  CAS  Google Scholar 

  34. Barnes GD, Li J, Kline-Rogers E, et al. Dual antiplatelet agent failure: a new syndrome or clinical nonentity? Am Heart J 2007 Oct; 154: 732–5

    Article  PubMed  CAS  Google Scholar 

  35. Grundmann K, Jaschonek K, Kleine B, et al. Aspirin nonresponder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003 Jan; 250: 63–6

    Article  PubMed  CAS  Google Scholar 

  36. Martin CP, Talbert RL. Aspirin resistance: an evaluation of current evidence and measurement methods. Pharmacotherapy 2005 Jul; 25: 942–53

    Article  PubMed  CAS  Google Scholar 

  37. Michelson AD, Cattaneo M, Eikelboom JW, et al., on behalf of the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3: 1309–11

    Article  PubMed  CAS  Google Scholar 

  38. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007 Jun; 115: 3156–64

    Article  PubMed  CAS  Google Scholar 

  39. Lau WC, Gurbel PA. Antiplatelet drug resistance and drug-drug interactions: role of cytochrome P450 3A 4. Pharm Res 2006 Dec; 23: 2691–708

    Article  PubMed  CAS  Google Scholar 

  40. Ivandic BT, Giannitsis E, Schlick P, et al. Determination of aspirin responsiveness by use of whole blood platelet aggregometry. Clin Chem 2007 Apr; 53: 614–9

    Article  PubMed  CAS  Google Scholar 

  41. Poulsen TS, Jørgensen B, Korsholm L, et al. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb Res 2007; 119: 555–62

    Article  PubMed  CAS  Google Scholar 

  42. Hobikoglu GF, Norgaz T, Aksu H, et al. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol 2007 Mar; 23: 201–6

    Article  PubMed  CAS  Google Scholar 

  43. Coleman JL, Wang JC, Simon DI. Determination of individual response to aspirin therapy using the Accumetrics Ultegra RPFA-ASA system. Point of Care 2004 Jun; 3: 77–82

    Google Scholar 

  44. Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007 Jul; 120: 631–5

    Article  PubMed  CAS  Google Scholar 

  45. Seok JI, Joo IS, Yoon JH, et al. Can aspirin resistance be clinically predicted in stroke patients? Clin Neurol Neurosurg 2008 Feb; 110: 110–6

    Article  PubMed  Google Scholar 

  46. Harrison P, Segal H, Blasbery K, et al. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005 May; 36: 1001–5

    Article  PubMed  CAS  Google Scholar 

  47. Chakroun T, Addad F, Abderazek F, et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. Thromb Res 2007; 121: 413–8

    Article  PubMed  CAS  Google Scholar 

  48. Dichiara J, Bliden KP, Tantry US, et al. Platelet function measured by VerifyNow® identifies generalized high platelet reactivity in aspirin treated patients. Platelets 2007 Sep; 18: 414–23

    Article  PubMed  CAS  Google Scholar 

  49. Ferroni P, Basili S, Falco A, et al. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004 Aug; 2: 1282–91

    Article  PubMed  CAS  Google Scholar 

  50. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005 Aug; 54: 2430–5

    Article  PubMed  CAS  Google Scholar 

  51. Zimmermann N, Kurt M, Winter J, et al. Aspirin-induced platelet inhibition in patients undergoing cardiac surgery. Platelets 2007 Nov; 18: 528–34

    Article  PubMed  CAS  Google Scholar 

  52. Modica A, Karlsson F, Mooe T. Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. J Thromb Haemost 2007 Mar; 5: 507–11

    Article  PubMed  CAS  Google Scholar 

  53. Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 2004 Jun; 109: 3064–7

    Article  PubMed  Google Scholar 

  54. Fitzgerald DJ, Maree A. Aspirin and clopidogrel resistance. Hematology Am Soc Hematol Educ Program 2007; 114-20

  55. Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007 Dec; 17: 1057–64

    Article  PubMed  CAS  Google Scholar 

  56. Kim KA, Park PW, Hong SJ, et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008 Aug; 84: 236–42

    Article  PubMed  CAS  Google Scholar 

  57. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006 Oct; 108: 2244–7

    Article  PubMed  CAS  Google Scholar 

  58. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006 Aug; 26: 1895–900

    Article  PubMed  CAS  Google Scholar 

  59. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009 Jan; 360: 354–62

    Article  PubMed  CAS  Google Scholar 

  60. Simon T, Verstuyft C, Mary-Krause M, et al., French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009 Jan; 360: 363–75

    Article  PubMed  CAS  Google Scholar 

  61. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008 Jan; 51: 256–60

    Article  PubMed  CAS  Google Scholar 

  62. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008 Apr; 48: 475–84

    Article  PubMed  CAS  Google Scholar 

  63. U.S. Food and Drug Administration. Clopidogrel (marketed as Plavix) and omeprazole (marketed as Prilosec): drug interaction [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190848.htm [Accessed 2010 Sep 6]

  64. Ben-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol 2009; 104: 227–33

    Article  PubMed  CAS  Google Scholar 

  65. Prabhakaran S, Wells KR, Lee VH, et al. Prevalence and 2 risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008 Feb; 29: 281–5

    Article  PubMed  CAS  Google Scholar 

  66. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822–34

    Article  PubMed  CAS  Google Scholar 

  67. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003 Jun; 107: 2908–13

    Article  PubMed  Google Scholar 

  68. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004 Jun; 109: 3171–5

    Article  PubMed  CAS  Google Scholar 

  69. Bonello L. Platelet monitoring of clopidogrel response using VASP phosphorylation index decreases rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. American College of Cardiology Scientific Sessions/i2 Summit-SCAI Annual Meeting; 2008 Mar 29; Chicago (IL). Late breaking clinical trials I [online]. Available from URL: http://www.theheart.org/article/850995.do [Accessed 2010 Sep 6]

  70. Pride YB, Wiviott SD, Buros JL, et al., TIMI Study Group. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Am Heart J 2009 Sep; 158(3): e21–6

    Article  PubMed  CAS  Google Scholar 

  71. Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008 Dec 9; 52(24): 1968–77

    Article  PubMed  CAS  Google Scholar 

  72. Eisert WG. Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells. Neurology 2001; 57(5 Suppl. 2): S20–3

    Article  PubMed  CAS  Google Scholar 

  73. Derendorf H, Estes K. The significance of optimised formulation for dipyridamole in stroke risk reduction. Eur Neurol Dis 2007; (2): 21-3

  74. Serebruany V, Malinin A, Ziai W, et al. Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness. Cerebrovasc Dis 2006; 21: 98–105

    Article  PubMed  CAS  Google Scholar 

  75. Aktas B, Utz A, Hoenig-Liedl P, et al. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke 2003 Mar; 34: 764–9

    Article  PubMed  CAS  Google Scholar 

  76. Cayla G, Macia JC, Rabesandratana H, et al. Flow cytometric assessment of vasodilator-stimulated phosphoprotein: prognostic value of recurrent cardiovascular events after acute coronary syndromes. Arch Cardiovasc Dis 2008 Nov–Dec; 101: 743–51

    Article  PubMed  Google Scholar 

  77. ESPRIT Study Group, Halkes PH, van Gijn J, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006 May; 367: 1665–73

    Article  PubMed  CAS  Google Scholar 

  78. Diener HC, Darius H, Bertrand-Hardy JM, et al. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 2001 Apr; 55: 162–3

    PubMed  CAS  Google Scholar 

  79. Patel D, Moonis M. Clinical implications of aspirin resistance. Expert Rev Cardiovasc Ther 2007 Sep; 5: 969–75

    Article  PubMed  CAS  Google Scholar 

  80. Hirsh J, Guyatt G, Albers GW, et al., American College of Chest Physicians. Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008 Jun; 133(6 Suppl. ): 110S–2S

    Article  PubMed  Google Scholar 

  81. Takahashi S, Ushida M, Komine R, et al. Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res 2007; 119: 517–24

    Article  PubMed  CAS  Google Scholar 

  82. Frelinger 3rd AL, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006 Jun; 113: 2888–96

    Article  PubMed  CAS  Google Scholar 

  83. Dropinski J, Jakiela B, Sanak M, et al. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. Thromb Haemost 2007 Jul; 98: 201–9

    PubMed  CAS  Google Scholar 

  84. Tirnaksiz E, Pamukcu B, Oflaz H, et al. Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. J Thromb Thrombolysis 2009 Jan; 27: 2724–8

    Article  Google Scholar 

  85. Cannon CP, Harrington RA, James S, et al., PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010 Jan 23; 375(9711): 283–93

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). Writing and editorial assistance was provided by Michele S. Olsher, PhD, and Julia Wenniger, PhD, of Publication CONNEXION (Newtown, PA, USA), which was contracted by BIPI for these services. Dr Greer meets criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE), was fully responsible for all content and editorial decisions and was involved at all stages of manuscript development. Dr Greer has received speaker’s honoraria from BIPI for educational talks, as well as research grant support from BIPI.

Author information

Authors and Affiliations

  1. ACC 739A, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts, 02114, USA

    David M. Greer

Authors
  1. David M. Greer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Greer, D.M. Aspirin and Antiplatelet Agent Resistance. CNS Drugs 24, 1027–1040 (2010). https://doi.org/10.2165/11539160-0000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11539160-0000000000-00000

Keywords

Search

Navigation